vs

Side-by-side financial comparison of Bankwell Financial Group, Inc. (BWFG) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

Bankwell Financial Group, Inc. is the larger business by last-quarter revenue ($30.3M vs $19.6M, roughly 1.6× STANDARD BIOTOOLS INC.). On growth, Bankwell Financial Group, Inc. posted the faster year-over-year revenue change (43.3% vs -11.5%). Bankwell Financial Group, Inc. produced more free cash flow last quarter ($27.1M vs $-23.1M). Over the past eight quarters, Bankwell Financial Group, Inc.'s revenue compounded faster (17.2% CAGR vs -12.2%).

Bankwell Financial Group, Inc. is a US-based bank holding company that provides a full suite of personal and commercial banking products and services, including deposit accounts, mortgage loans, commercial lending, and wealth management solutions. It primarily serves local communities, retail customers, and small to medium-sized enterprises across Connecticut.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

BWFG vs LAB — Head-to-Head

Bigger by revenue
BWFG
BWFG
1.6× larger
BWFG
$30.3M
$19.6M
LAB
Growing faster (revenue YoY)
BWFG
BWFG
+54.8% gap
BWFG
43.3%
-11.5%
LAB
More free cash flow
BWFG
BWFG
$50.2M more FCF
BWFG
$27.1M
$-23.1M
LAB
Faster 2-yr revenue CAGR
BWFG
BWFG
Annualised
BWFG
17.2%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
BWFG
BWFG
LAB
LAB
Revenue
$30.3M
$19.6M
Net Profit
$-34.7M
Gross Margin
48.5%
Operating Margin
46.9%
-168.5%
Net Margin
-177.4%
Revenue YoY
43.3%
-11.5%
Net Profit YoY
-28.8%
EPS (diluted)
$1.16
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BWFG
BWFG
LAB
LAB
Q4 25
$30.3M
Q3 25
$28.5M
$19.6M
Q2 25
$25.9M
$21.8M
Q1 25
$23.6M
$40.8M
Q4 24
$21.2M
Q3 24
$21.9M
$22.1M
Q2 24
$21.9M
$22.5M
Q1 24
$22.1M
$45.5M
Net Profit
BWFG
BWFG
LAB
LAB
Q4 25
Q3 25
$10.1M
$-34.7M
Q2 25
$9.1M
$-33.5M
Q1 25
$6.9M
$-26.0M
Q4 24
Q3 24
$1.9M
$-26.9M
Q2 24
$1.1M
$-45.7M
Q1 24
$3.8M
$-32.2M
Gross Margin
BWFG
BWFG
LAB
LAB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
BWFG
BWFG
LAB
LAB
Q4 25
46.9%
Q3 25
47.3%
-168.5%
Q2 25
45.5%
-118.1%
Q1 25
38.0%
-80.8%
Q4 24
19.2%
Q3 24
12.4%
-120.9%
Q2 24
6.7%
-134.5%
Q1 24
23.0%
-132.2%
Net Margin
BWFG
BWFG
LAB
LAB
Q4 25
Q3 25
35.4%
-177.4%
Q2 25
35.0%
-153.7%
Q1 25
29.2%
-63.8%
Q4 24
Q3 24
8.8%
-122.0%
Q2 24
5.1%
-203.3%
Q1 24
17.1%
-70.6%
EPS (diluted)
BWFG
BWFG
LAB
LAB
Q4 25
$1.16
Q3 25
$1.27
$-0.09
Q2 25
$1.15
$-0.09
Q1 25
$0.87
$-0.07
Q4 24
$0.37
Q3 24
$0.24
$-0.07
Q2 24
$0.14
$-0.12
Q1 24
$0.48
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BWFG
BWFG
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$192.1M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$301.5M
$399.7M
Total Assets
$3.4B
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BWFG
BWFG
LAB
LAB
Q4 25
$192.1M
Q3 25
$128.2M
$129.4M
Q2 25
$142.6M
$158.6M
Q1 25
$136.0M
$150.9M
Q4 24
$146.1M
Q3 24
$145.9M
$210.6M
Q2 24
$138.0M
$269.8M
Q1 24
$126.2M
$287.1M
Total Debt
BWFG
BWFG
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
BWFG
BWFG
LAB
LAB
Q4 25
$301.5M
Q3 25
$292.8M
$399.7M
Q2 25
$283.3M
$424.5M
Q1 25
$275.2M
$454.6M
Q4 24
$270.5M
Q3 24
$267.9M
$489.3M
Q2 24
$267.0M
$510.3M
Q1 24
$268.0M
$577.3M
Total Assets
BWFG
BWFG
LAB
LAB
Q4 25
$3.4B
Q3 25
$3.2B
$539.6M
Q2 25
$3.2B
$557.0M
Q1 25
$3.2B
$579.6M
Q4 24
$3.3B
Q3 24
$3.2B
$681.5M
Q2 24
$3.1B
$708.7M
Q1 24
$3.2B
$777.7M
Debt / Equity
BWFG
BWFG
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BWFG
BWFG
LAB
LAB
Operating Cash FlowLast quarter
$28.3M
$-22.2M
Free Cash FlowOCF − Capex
$27.1M
$-23.1M
FCF MarginFCF / Revenue
89.5%
-118.1%
Capex IntensityCapex / Revenue
3.8%
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$47.0M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BWFG
BWFG
LAB
LAB
Q4 25
$28.3M
Q3 25
$10.3M
$-22.2M
Q2 25
$6.5M
$-20.7M
Q1 25
$3.9M
$-30.3M
Q4 24
$29.9M
Q3 24
$-557.0K
$-27.9M
Q2 24
$7.1M
$-39.0M
Q1 24
$9.0M
$-62.5M
Free Cash Flow
BWFG
BWFG
LAB
LAB
Q4 25
$27.1M
Q3 25
$9.9M
$-23.1M
Q2 25
$6.1M
$-22.6M
Q1 25
$3.8M
$-35.3M
Q4 24
$29.3M
Q3 24
$-672.0K
$-30.1M
Q2 24
$6.8M
$-41.0M
Q1 24
$8.9M
$-63.3M
FCF Margin
BWFG
BWFG
LAB
LAB
Q4 25
89.5%
Q3 25
34.9%
-118.1%
Q2 25
23.5%
-103.6%
Q1 25
16.2%
-86.6%
Q4 24
138.6%
Q3 24
-3.1%
-136.4%
Q2 24
31.0%
-182.2%
Q1 24
40.5%
-138.9%
Capex Intensity
BWFG
BWFG
LAB
LAB
Q4 25
3.8%
Q3 25
1.4%
4.5%
Q2 25
1.5%
8.7%
Q1 25
0.4%
12.4%
Q4 24
2.9%
Q3 24
0.5%
10.2%
Q2 24
1.7%
8.6%
Q1 24
0.4%
1.7%
Cash Conversion
BWFG
BWFG
LAB
LAB
Q4 25
Q3 25
1.03×
Q2 25
0.71×
Q1 25
0.57×
Q4 24
Q3 24
-0.29×
Q2 24
6.39×
Q1 24
2.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BWFG
BWFG

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons